Safinamide in the management of patients with Parkinson's disease not stabilized on levodopa: a review of the current clinical evidence

about

Safinamide in the management of patients with Parkinson's disease not stabilized on levodopa: a review of the current clinical evidence

Item

http://www.wikidata.org/entity/Q57074141

description

article

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2018

@uk

name

Safinamide in the management o ...... the current clinical evidence

@en

Safinamide in the management o ...... the current clinical evidence

@nl

type

Item

label

Safinamide in the management o ...... the current clinical evidence

@en

Safinamide in the management o ...... the current clinical evidence

@nl

prefLabel

Safinamide in the management o ...... the current clinical evidence

@en

Safinamide in the management o ...... the current clinical evidence

@nl

P1476

Safinamide in the management o ...... the current clinical evidence

@en

P2093

Carlos Singer

http://www.w3.org/2001/XMLSchema#string

Henry Moore

http://www.w3.org/2001/XMLSchema#string

Sagari Bette

http://www.w3.org/2001/XMLSchema#string

P2860

Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs

An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells.

Effects of ketoconazole treatment on the pharmacokinetics of safinamide and its plasma metabolites in healthy adult subjects.

Pharmacological treatment of Parkinson disease: a review.

Safinamide: from molecular targets to a new anti-Parkinson drug.

Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations.

Relating mode of action to clinical practice: dopaminergic agents in Parkinson's disease.

Safinamide as Add-On Therapy to Levodopa in Mid- to Late-Stage Parkinson's Disease Fluctuating Patients: Post hoc Analyses of Studies 016 and SETTLE

Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial.

Safinamide: first global approval.

P304

1737-1745

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/TCRM.S139545

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

Danielle S Shpiner

P577

2018-09-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30271159

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

levodopa

P932

6152599

http://www.w3.org/2001/XMLSchema#string